Interim Report and Half-Year Financial Results

Feb 25th, 2021

Starpharma today released its interim report and financial results for the half-year ended 31 December 2020.

Read More

Channel 7 News reports Starpharma's VIRALEZE has been registered in the UK/Europe

Feb 23rd, 2021

 

Channel 7 News (Melbourne) reports Starpharma's VIRALEZE™ has been registered in the UK/Europe. Watch here

 

 

Read More

VIRALEZE™ antiviral nasal spray registered in Europe

Feb 23rd, 2021

Starpharma announced today it had received confirmation that the VIRALEZE™ antiviral nasal spray has been successfully registered for sale in Europe, including in the UK.

Read More

Starpharma signs research agreement with MSD

Feb 12th, 2021

The Market Herald reported that Starpharma signed a Research Agreement with Merck & Co., Inc., Kenilworth NJ USA for dendrimer-based Antibody Drug Conjugates (ADCs) utilising Starpharma’s proprietary DEP® technology. Read more here

Read More

Starpharma signs DEP® ADC Research Agreement with MSD

Feb 12th, 2021

Starpharma today announced that is has signed a Research Agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth NJ USA. Under the agreement, MSD will conduct a preclinical research evaluation of dendrimer based Antibody Drug Conjugates (ADCs) utilising Starpharma’s proprietary DEP® technology.

 

Read More

Ausbiz interviews Starpharma CEO Dr Jackie Fairley

Feb 10th, 2021

Finance and market news website AusBiz interviewed Starpharma CEO Dr Jackie Fairley to discuss the global expansion of AstraZeneca’s clinical trial for AZD0466 and their multi-product DEP® licence with Starpharma. She also spoke about the upcoming launch of VIRALEZE in Europe. Watch the interview here.

 

Read More

AZD0466 clinical DEP® program global expansion

Feb 9th, 2021

Starpharma today announced that it had been advised by AstraZeneca of its intention to expand the clinical program for AZD0466 to include a multi-centre global Phase 1 study. The study will recruit patients with acute leukaemias.

Read More

Aussie condom antiviral recruited for Covid-19 fight

Feb 4th, 2021

The Australian interviewed Starpharma CEO Dr Jackie Fairley regarding Starpharma’s plans for the European launch of VIRALEZE™ antiviral nasal spray. Read article here.

Read More

Australian-developed COVID nasal spray set to land in Europe

Feb 4th, 2021

Biotech Dispatch reported on Starpharma's launch plans for VIRALEZE™ in Europe. Read the full article here.

Read More

Channel 7 evening news features Starpharma's VIRALEZE

Feb 3rd, 2021

Watch Laurel Irving Channel 7 News (Melbourne) interview Dr Jackie Fairley, CEO of Starpharma about VIRALEZE™ and the need for other COVID-19 preventative tools alongside vaccines. 

Read More

Starpharma prepares to launch COVID-killing nasal spray

Feb 2nd, 2021

Alan Kohler spoke with Dr Jackie Fairley, CEO of Starpharma about the launch of its VIRALEZE™ antiviral nasal spray, for the Eureka Report. Listen to the interview here.

Read More

Quarterly Cashflow and Activity Report

Jan 29th, 2021

Starpharma released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 December 2020.

Read More

Leading broker names the ASX healthcare shares to buy in 2021

Jan 9th, 2021

The Motley Fool reported that Starpharma has been named by analysts at Bell Potter "one of ASX shares from several industries that they believe are best placed to have a strong 2021".

To read the full article, click here

Read More

VIRALEZE COVID-19 nasal spray study to commence in January

Dec 22nd, 2020

Starpharma today announced that it has received all necessary approvals to commence its clinical study for VIRALEZE™. The study will commence enrolment of healthy volunteers in Perth in early January 2021 and is expected to be completed in Q1 2021. This study is being undertaken to support commercialisation activities for VIRALEZE™, and is not a requirement to achieve EU product registration.  

Read More

VIRALEZE™ COVID-19 nasal spray to be ready for market Q1CY21

Dec 10th, 2020

Starpharma today announced significant commercial and regulatory progress has been made for VIRALEZE™ nasal spray with the EU regulatory dossier more than 90% complete and VIRALEZE™ now on track to be registered, and ready for market in Q1 CY2021. This timing is earlier than previously announced.

Read More

Starpharma Viraleze: COVID-19 Nasal Spray Development

Nov 20th, 2020

Seeking Alpha, a financial market portal featured a piece on Starpharma’s latest update on its VIRALEZE™ COVID-19 nasal spray. The article noted the potential of the spray and Starpharma’s latest regulatory developments on this front. To read the full article click here.

Read More

AGM Chairman address and CEO presentation

Nov 20th, 2020

Attached is the Chairman’s address together with the CEO’s presentation to the Annual General Meeting (AGM) of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), to be held at 11am (Melbourne time) today.

 

Read More

SPL7013 shows potent antiviral activity in RSV expanding use for nasal spray

Nov 19th, 2020

Starpharma today announced it has completed additional testing showing potent antiviral activity of SPL7013 against human respiratory syncytial virus (RSV). RSV is a common and very contagious virus that affects the lungs and airways. RSV is most problematic in the young and the elderly and those with weakened immune systems, or chronic heart and lung disease, including asthma. More than 177,000 adults are hospitalized and 14,000 of them die due to RSV infection in the US annually. RSV is also one of the viruses responsible for the common cold.

 

Read More

Quarterly Cashflow and Activities Report

Oct 30th, 2020

Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 September 2020.

Read More

Completion of Placement and SPP raises $48.9M in total

Oct 29th, 2020

Starpharma today announced that it has completed its Share Purchase Plan (SPP), raising $3.9 million. The SPP was conducted in conjunction with Starpharma’s recent institutional placement (Placement), which together have raised a total of $48.9 million. The issue of 2.6 million new shares under the SPP will be at $1.50 per share, being equivalent to the Placement share price.

 

Read More

Starpharma (ASX:SPL) banks $5.7M government R&D tax refund

Oct 21st, 2020

The Market Herald reported that Starpharma are to receive a $5.7 million research and development (R&D) tax incentive refund from the Federal Government following the government’s program to  support companies taking on R&D that benefits Australia. To watch the full video click here.

Read More

Starpharma receives $5.7M R&D tax incentive refund

Oct 21st, 2020

Starpharma today announced that it has received a $5.7M R&D tax incentive refund which relates to the costs of research and development during the 2020 Financial Year. The refund is in respect of eligible R&D activities across Starpharma’s portfolio, including for COVID-19, DEP® and VivaGel® programs.

Read More

Shareholder Update October 2020

Oct 20th, 2020

In this issue:

>> Starpharma is expediting the development of the SPL7013 COVID‑19 nasal spray

>> Rapid progress in the DEP® irinotecan phase 2 & preparations underway for clinical combinations

>> DEP® irinotecan in combination with immuno-oncology showed superior performance in colon cancer models

>> VivaGel® BV launched in Central & Eastern Europe and Nordic region

>> Fleurstat BVgel gains expanded TGA approval to include prevention of recurrent Bacterial Vaginosis (BV) indication

>> VivaGel® BV has now been approved in 40 countries with further submissions underway

>> Starpharma awarded $1 million MRFF funding for COVID-19 nasal spray

>> DEP® docetaxel update & patient case study

>> DEP® cabazitaxel update & patient case study

>> Multiple DEP® products showcased at AACR 2020 Annual Meeting

>> New DEP® partnership signed with Chase Sun for anti-infective program

>> AstraZeneca’s AZD0466 trial opens at MD Anderson Cancer Center

>> Starpharma creates slow release soluble DEP® remdesivir

>> DEP® partnering, including Antibody Drug Conjugates

>> DEP® lutetium; impressive efficacy in human prostate cancer model

>> Outlook, Annual Report & ESG Report & recent news 

Read More

Biotech In Focus In 2020

Oct 16th, 2020

Online financial news platform FN Arena recently published an article which highlighted six biotech ASX-listed companies that have recently been viewed positively by analysts. Starpharma was listed as one such company, stating that Bell Potter had emphasized the company’s strong growth potential. To read the full article click here

Read More

$2B R&D win for biotech, resources

Oct 8th, 2020

Starpharma was featured in an article by Stockhead, an online publication that delivers news on ASX-listed small and mid-cap companies. The piece looked at the Federal Government’s decision to abandon plans to reduce R&D tax refund by $1.8B, and will instead add $200M in value to the incentive. The article noted Starpharma received a $4.9M tax refund in December 2019 for R&D associated with the development of its DEP drug delivery system and VivaGel BV women’s health products.

To read the full article click here.

 

Read More

Allianz ups Starpharma stake as M&G sells

Oct 8th, 2020

On 8 October, Starpharma was included in the SMH’s live market update which reported Allianz Global Investors had upped its stake in Starpharma after buying close to 10 million additional shares. It added that the fund’s position in the company had risen from 5 to 7.1 per cent. To read the full article click here

Read More

Share Purchase Plan offer document

Oct 7th, 2020

Starpharma provides the offer document for the Company's 2020 Share Purchase Plan (SPP).

Read More

Starpharma completes oversubscribed A$45M placement - SPP to follow

Sep 30th, 2020

Starpharma today announced that it has raised A$45 million via a placement to domestic and international institutional, sophisticated and professional investors (“Placement”). Eligible shareholders will also have the opportunity to participate, at the same price, through a Share Purchase Plan (SPP) which is expected to raise approximately A$5 million.

Read More

Investor Presentation

Sep 30th, 2020

Starpharma today provided its latest investor presentation.

 

Read More

VivaGel® BV secures TGA approval for prevention of BV

Sep 25th, 2020

Starpharma today announced that the Australia Therapeutic Goods Administration (TGA) has approved an expansion of the marketing authorisation for VivaGel® BV (Fleurstat BVgel) to now include the indication of prevention of recurrent bacterial vaginosis. These expanded claims bring the approved indications for VivaGel® BV (Fleurstat BVgel) in line with those in Europe and Asia.

Read More

Starpharma is interviewed by Stockhead to give a company overview and provide an update on its COVID-19 nasal spray

Sep 17th, 2020

Stockhead’s Tim Boreham interviewed Starpharma CEO Jackie Fairley for their Health Kick Podcast. Tim reported that Starpharma has gone from strength to strength following progress on its COVID-19 nasal spray. To hear an overview of the company, and update on current development programs and plans for the year ahead, listen to the full episode here

Read More

Starpharma to present at OTCQX Life Sciences Investor Forum

Sep 17th, 2020

Starpharma today announced that a pre-recorded presentation by Dr Jackie Fairley, CEO, will be broadcast on Thursday 17 September 2020 (US ET) as part of OTCQX’s Life Sciences Investor Forum.

Read More

SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2

Sep 14th, 2020

Starpharma today announced it has completed additional antiviral testing for SPL7013 against SARS‑CoV-2 in studies conducted in the laboratory of internationally recognised virology researcher, Professor Philippe Gallay, at the renowned Scripps Research Institute in the US.

Read More

Starpharma awarded $1M MRFF funding for COVID-19 spray

Sep 3rd, 2020

Starpharma today announced the award of $1 million in matched funding by the Australian Government’s Medical Research Future Fund (MRFF) Biomedical Translation Bridge (BTB) Program to expedite development and commercialisation of its COVID‑19 antiviral nasal spray based on Starpharma’s proprietary dendrimer, SPL7013.

 

Read More

SPL creates slow release soluble DEP® remdesivir nanoparticle

Sep 1st, 2020

Starpharma today announced it has applied its novel DEP® drug delivery technology to create a long‑acting, water soluble version of remdesivir. Remdesivir is an antiviral drug, currently being developed by Gilead to treat COVID-19 and has emergency use authorisation from the US Food and Drug Administration for the treatment of COVID-19 in adults and children hospitalised with severe disease.

Read More

Annual report and full year financial results

Aug 27th, 2020

Melbourne, Australia: Starpharma today released its annual report and financial results for the year ended 30 June 2020.

Read More

2GB’s Jim Wilson interviews Starpharma CEO Dr Jackie Fairley

Aug 26th, 2020

2GB radios Jim Wilson interviewed Starpharma CEO Dr Jackie Fairley to get an update on how Starpharma is fast-tracking a nasal spray designed to be used as a preventative measure in the fight against COVID-19.

To listen to the full interview click here.

Read More

ABC News features Starpharma on ‘The Kohler Report’

Aug 26th, 2020

Starpharma was featured on ABC’s  finance news segment ‘The Kohler Report’, where Alan Kohler highlighted that Starpharma shares had risen 23% following the Company’s update on its SPL7013-based antiviral nasal spray, which has shown to have potent antiviral activity against COVID-19. The update included that Starpharma has commenced confidential commercial discussions with related parties.

To watch the full report, click here.

Read More

Australian Manufacturing writes about Starpharma identifying a manufacturer of its antiviral nasal spray for COVID-19

Aug 26th, 2020

Starpharma was recently featured in an article by Australian Manufacturing, a leading publication and resource for the manufacturing and industrial sector in Australia. The article noted Starpharma had undertaken a pilot manufacture for its SPL7013 antiviral nasal spray, which has been tested and confirmed to have potent antiviral activity against SARS-CoV-2, the virus that causes COVID-19. The article also highlightsed SPL has identified a manufacturer and are currently compiling documentation in preparation for regulatory submission.

To read the full article click here.

Read More

SPL7013 nasal spray for COVID-19 – development update

Aug 25th, 2020

Starpharma today announced progress with development, regulatory and manufacturing activities associated with a nasal spray for protection against COVID-19 based on the company’s proprietary antiviral dendrimer, SPL7013.

Read More

Starpharma signs new DEP® partnership with Chase Sun

Aug 17th, 2020

Starpharma today announced that it has signed a new research partnership with leading Chinese Pharmaceutical company Tianjin Chase Sun Pharmaceutical Co., Ltd. (stock code 300026; Chase Sun), to develop several DEP® nanoparticle formulations for an anti-infective drug. The agreement also provides for the potential to conduct additional DEP® programs, which can be across therapeutic areas beyond anti-infectives.

 

Read More

Quarterly Cashflow and Activities Report

Jul 30th, 2020

Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 June 2020.

Read More

DEP® docetaxel and gemcitabine combination trial commences

Jul 30th, 2020

Starpharma today announced that it has commenced its DEP® docetaxel + gemcitabine combination study for patients with advanced cancers, including pancreatic cancer. Recruitment into the study has commenced at the Christie in the UK, with two further sites expected to open in the coming weeks.

 

Read More

AZD0466 trial opens MD Anderson Cancer Center as a site

Jul 27th, 2020

Starpharma (ASX: SPL, OTCQX: SPHRY) today announced the opening of the MD Anderson Cancer Center as a further trial site for the phase 1 trial of AZD0466, AstraZeneca’s first DEP® product.

Read More

New Australian site opening for DEP® trials

Jul 9th, 2020

Starpharma today announced the opening of a new trial site for the phase 2 DEP® irinotecan trial, at the Kinghorn Cancer Centre in Sydney. The DEP® irinotecan trial is also being conducted at multiple leading UK cancer centres including The Christie, The Royal Marsden, Newcastle Freeman Hospital, and The Beatson West of Scotland Cancer Centre. The Kinghorn Cancer Centre will also be opened shortly as an additional site for the phase 2 DEP® cabazitaxel trial.

 

Read More

The Age: Starpharma CEO Dr Jackie Fairley on Australia’s need to turn homegrown research into commercial products

Jul 3rd, 2020

The Age interviewed Starpharma CEO Dr Jackie Fairley about how the COVID-19 pandemic could be the much needed catalyst for the pharmaceutical industry to improve the way they convert important research into commercial products. Dr Fairley also covered Starpharma’s recent activities in response to the pandemic including, the development of a nasal spray product using the antiviral dendrimer, SPL7013.

To read the full interview click here.

Read More

Pandemic a catalyst for boosting commercial outcomes, says Starpharma CEO

Jul 3rd, 2020

The Age recently interviewed Starpharma CEO Dr Jackie Fairley to discuss how the COVID19 pandemic could be the catalyst for the pharmaceutical industry to improve the way they convert important research into commercial products. The article highlighted Starpharma’s recent activities in response to the pandemic, including the development of a product using its existing anti-viral dendrimer SPL7013.

To read the full article, click here.

Read More

DEP irinotecan boosts immuno-oncology in colon cancer models

Jun 29th, 2020

Starpharma today announced its SN-38 nanoparticle, DEP® irinotecan in combination with an immuno-oncology (IO) agent (anti PD-1 antibody) showed superior anti-tumour activity and significant survival benefit in two colorectal cancer (CRC) models when compared to the anti PD-1 antibody alone. These results included improvement in both survival and efficacy in the particularly aggressive CT-26 CRC model.

Read More

The 7.30 report interviews Starpharma CEO Dr Jackie Fairley

Jun 25th, 2020

The ABC’s 7:30 report interviewed Starpharma CEO Dr Jackie Fairley to discuss the importance of creating COVID-19 preventative products while the world waits for a vaccine to be developed. Dr Fairley discussed how Starparma’s patented dendrimer SPL7013 has shown significant anti-viral activity against SARS-CoV-2 (coronavirus) and how quickly a product using this ingredient could be brought to market given its approval and use in other marketed products.

Watch the full interview click here.

Read More

Starpharma CEO Dr Jackie Fairley on the ABC’s 7.30 report

Jun 25th, 2020

Alan  Kohler recently interviewed Starpharma CEO Dr Jackie Fairley on the ABC’s 7.30 report to discuss the importance of developing other methods of protection against  COVID-19 while we wait for a vaccine. Jackie also discusses how Starpharma’s patented dendrimer SPL7013 is being developed for use in an antiviral nasal spray to prevent COVID-19 infection.

Watch the full interview here: https://www.abc.net.au/7.30/how-long-will-the-economy-take-to-recover/12394342

Read More